BMS-275183

DRUG2 trials

Sponsors

Bristol-Myers Squibb

Conditions

Non-small Cell Lung CancerTumors

Phase 1

A Phase I Study of BMS-275183 Given on a Daily Schedule in Patients With Advanced Malignancies

TerminatedNCT00207025

Bristol-Myers SquibbTumors

Start: 2004-10-31Target: 60Updated: 2010-03-02

Phase 2

Study of BMS-275183 in Patients With Pre-treated Non-small Cell Lung Cancer

TerminatedNCT00099879

Bristol-Myers SquibbNon-small Cell Lung Cancer

Updated: 2010-03-02